My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Emergent BioSolutions Inc. Common Stock
(NY:
EBS
)
9.070
-0.970 (-9.66%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Emergent BioSolutions Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
October 08, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 02, 2025
Via
Benzinga
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
September 24, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Earnings Scheduled For August 6, 2025
August 06, 2025
Via
Benzinga
A Preview Of Emergent BioSolutions's Earnings
August 05, 2025
Via
Benzinga
3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts
September 24, 2025
Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment
Via
MarketBeat
Topics
Economy
Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’
September 19, 2025
The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.
Via
Stocktwits
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
September 19, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
September 15, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
September 09, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
September 02, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
August 29, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Participate in Upcoming Investor Conferences
August 27, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
August 21, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Big Rallies Brewing? 3 Analyst Favorites to Watch Closely
August 18, 2025
Despite share price pops after earnings, SKYT, EBS, and BLZE may still have room to rally further, as each firm has garnered strong analyst support.
Via
MarketBeat
Thursday's session: top gainers and losers
August 07, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
August 07, 2025
Via
Benzinga
Traders are paying attention to the gapping stocks in Thursday's session.
August 07, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 06, 2025
Via
Benzinga
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
July 28, 2025
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
July 28, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
July 15, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy
July 08, 2025
The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray.
Via
Stocktwits
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
July 08, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
July 02, 2025
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
June 23, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Addition to Russell 3000® Index
June 20, 2025
From
Emergent BioSolutions
Via
GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
June 18, 2025
From
FN Media Group LLC
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.